ReadCoor to Present at the 11th Annual Canaccord Genuity
Medical Technology & Diagnostics Forum
Cambridge, Mass. November 2, 2017 –(BUSINESS WIRE) – ReadCoor, Inc., a company reinventing omics and pathology with its panomic spatial sequencing platform, FISSEQ, today announced that Shawn Marcell, Chief Executive Officer and Chairman of the Board, will present a company overview at the 11th Annual Canaccord Genuity Medical Technology & Diagnostics Forum in New York, NY. The presentation will take place on November 9, 2017 at 2:00 PM EST.
About Fluorescent in situ Sequencing (FISSEQ)
FISSEQ is a spatial sequencing technology that reads and visualizes the three-dimensional coordinates of molecules of intact tissue, a capability that stands to revolutionize panomics and pathology. FISSEQ was developed in the Church Lab at Harvard University and the Wyss Institute for Biologically Inspired Engineering, and first published in Science in 2014 (Highly multiplexed three-dimensional subcellular transcriptome sequencing in situ). The platform has broad application in the areas of drug development, diagnostics, and machine learning.
About ReadCoor, Inc.
ReadCoor is leading the next generation of omics by delivering the first panomic spatial sequencing platform to the global audience of researchers, clinicians, pharma and diagnostics companies, and ultimately patients. It is accomplishing this with Fluorescent in situ Sequencing (FISSEQ), a fundamental new technology, which simultaneously integrates high-throughput sequencing, and three-dimensional morphometric analysis. This uniquely powerful platform is expected to revolutionize the next phase in understanding the panomic landscape and introduce vast new opportunities for important and meaningful clinical insight.